表紙:バイオ医薬品賦形剤製造の世界市場 - 予測(2023年~2035年)
市場調査レポート
商品コード
1403891

バイオ医薬品賦形剤製造の世界市場 - 予測(2023年~2035年)

Biopharmaceutical Excipient Manufacturing Market- Forecast (2023-2035)"

出版日: | 発行: IndustryARC | ページ情報: 英文 108 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
バイオ医薬品賦形剤製造の世界市場 - 予測(2023年~2035年)
出版日: 2023年12月01日
発行: IndustryARC
ページ情報: 英文 108 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のバイオ医薬品賦形剤製造の市場規模は、2035年までに58億8,800万米ドルに達し、2023年~2035年にCAGRで4.9%の成長が見込まれています。市場の主な促進要因は、座りっぱなしのライフスタイルによる慢性疾患の増加、製薬企業による医薬品開発への多額の投資、ナノテクノロジーなどの新技術の導入です。例えば、世界保健機関(WHO)によると、2050年ごろまでに、心血管疾患、がん、糖尿病、呼吸器疾患などの慢性疾患が、毎年9,000万人の死因の86%を占めるようになります。しかし、バイオ医薬品産業が現在直面している主な課題は、医薬品の副作用と、環境にやさしい製造プロセスの開発です。

要点

  • 欧州は世界最大のバイオ医薬品賦形剤市場であり、2022年の市場シェアは33%に達します。欧州のバイオ医薬品賦形剤の市場規模は、2022年の10億3,000万米ドルから、地域の産業の大幅な成長により2035年までに17億6,000万米ドルに達し、2023年~2035年にCAGRで4.1%の成長が見込まれています。
  • 製薬企業は、米国の勢い、力強い内需、インドの旺盛な政府支出により、北米とアジア太平洋の経済状況をやや楽観視しています。アジア太平洋の市場規模は2022年に7億5,000万米ドル、2035年までに17億1,000万米ドルとなり、CAGRで6.4%の最速の成長が予測されています。
  • 機能別では、抗菌剤が2022年に24%の大きな市場シェアを占めました。賦形剤は生物製剤の開発において、溶解性とバイオアベイラビリティを向上させ、原薬のpHと強壮性を制御することで重要な役割を果たしています。さらに、バイオ医薬品賦形剤は、充填剤、酸化防止剤、防腐剤として機能します。

促進要因 - 生物医薬品賦形剤製造市場

製薬企業のジェネリック市場の重視

市場参入企業は、革新的なバイオ医薬品賦形剤の開発と商業化に注力しています。例えばDFE Pharmaは2021年4月、世界のバイオ医薬品ビジネスの供給難に対処するため、「BioHale」と呼ばれる新しい賦形剤製品ラインを発表しました。さらに、バイオ医薬品賦形剤の需要が高まるにつれて、製造施設は地理的に拡大しています。例えば、2022年5月、DFE Pharmaはインドに新たな施設を立ち上げ、製薬企業に賦形剤を含む迅速な製剤サービスを提供し、適切な製剤を調達しています。

多機能賦形剤の人気が高まる

業界の多機能バイオ医薬品賦形剤の受容も市場拡大の促進要因となっています。多機能バイオ医薬品賦形剤は、バイオ医薬品製造プロセスの改善に効率的かつ効果的です。製品の品質向上、生産の増加、運用コストの削減はすべて関連するメリットです。COVID-19ワクチンの成功は、効率的なドラッグデリバリーシステムの使用によって改良されたその有効性に大きく依存しています。Ludiflash、F-MELT、Avicel CE-15などの多機能賦形剤は、ODT製剤に向けて特別に作られたものです。これらは、圧縮中の結合性(低い圧力で硬い錠剤を製造すること)と、媒体にさらされた際の迅速な崩壊性を提供するためにカスタムメイドされています。よりクリーミーな口当たりで崩壊し、製剤全体の嗜好性を高めるような方法で取り扱われます。状況によっては(マンニトールを約90%含むルディフラッシュなど)、賦形剤自体が製品に甘味を与え、製剤中の甘味料の必要性を低減します。

当レポートでは、世界のバイオ医薬品賦形剤製造市場について調査し、市場シェア、促進要因、セグメント、地域、主要企業などの分析を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 章の概要
  • バイオ医薬品賦形剤
  • 理想的な賦形剤の特性
  • バイオ医薬品賦形剤の分類
  • バイオ医薬品賦形剤の用途
  • 規制シナリオ
  • 結論

第4章 市場情勢

  • 章の概要
  • バイオ医薬品賦形剤メーカー:全体的な市場情勢
    • 分析:設立年別
    • 分析:企業規模別
    • 分析:本社所在地別
    • 分析:バイオ医薬品賦形剤製造施設の所在地別
  • 分析:化学組成に基づく賦形剤タイプ別
    • 炭水化物
    • ポリオール
    • ポリマー
    • タンパク質/アミノ酸
    • 脂質
    • その他
  • 分析:機能に基づいた賦形剤タイプ別
    • 界面活性剤
    • 安定剤
    • 張度調整剤
    • 充填剤
    • 緩衝剤
    • 溶解促進剤
    • ドラッグデリバリーシステム
    • キレート剤
    • 抗菌剤
    • 酸化防止剤
    • その他
  • 分析:化学構造に基づく賦形剤タイプ別
    • 有機
    • 無機
  • 分析:経営規模別
    • 前臨床
    • 臨床
    • 商業
  • 分析:製剤タイプ別
    • 液体または非経口
    • 固体
  • 分析:生物製剤タイプ別
    • ワクチン
    • タンパク質/ペプチド
    • 細胞療法
    • 抗体
    • 血液製剤
      • 分析:世界の規制順守別
    • 米国薬局方
    • 欧州薬局方
    • 日本薬局方
    • 英国薬局方
    • 中国薬局方
    • アメリカ化学会グレード
    • インド薬局方
    • FCC
    • 台湾FDA

第5章 企業の競争力の分析

  • 章の概要
  • 前提条件と主なパラメーター
  • 調査手法
  • バイオ医薬品賦形剤メーカー:企業の競争力の分析
    • 企業の競争力の分析:小企業
    • 企業の競争力の分析:中規模企業
    • 企業の競争力の分析:大企業
    • 企業の競争力の分析:超大企業

第6章 企業プロファイル:バイオ医薬品賦形剤メーカー

  • 章の概要
  • ABITEC
  • Avantor
  • BASF Pharma
  • Corden Pharma
  • DFE Pharma
  • Evonik
  • Kirsch Pharma
  • Merck KGaA
  • Pfanstiehl
  • Roquette
  • Spectrum Chemical Manufacturing
  • SPI Pharma

第7章 パートナーシップと提携

  • 章の概要
  • パートナーシップモデル
  • バイオ医薬品賦形剤製造市場:パートナーシップと提携
    • 分析:パートナーシップ年別
    • 分析:パートナーシップタイプ別
    • 分析:パートナーシップ年、タイプ別
    • 分析:賦形剤タイプ別
    • 分析:薬剤分子タイプ別
    • もっとも活発な企業:パートナーシップ数の分析
    • 分析:地域別

第8章 近年の拡張

  • 章の概要
  • バイオ医薬品賦形剤製造市場:近年の拡張
    • 分析:拡張年別
    • 分析:拡張タイプ別
    • 分析:企業規模、本社所在地別
    • 分析:拡張施設の所在地別
    • 分析:賦形剤タイプ別
    • 分析:薬剤分子タイプ別
    • もっとも活発な企業:近年の拡張数の分析
    • 地域の分析

第9章 生産能力の分析

  • 章の概要
  • 主な前提条件と調査手法
  • バイオ医薬品賦形剤製造:世界の稼働中の生産能力
    • 分析:企業規模別
    • 分析:経営規模別
    • 分析:製造施設の所在地別
  • 結論

第10章 市場予測、機会の分析

  • 章の概要
  • 予測手法と主な前提条件
  • 世界のバイオ医薬品賦形剤製造市場(2022年~2035年)
  • バイオ医薬品賦形剤製造市場:生物製剤タイプ別(2022年・2035年)
  • バイオ医薬品賦形剤製造市場:賦形剤タイプ別(2022年・2035年)
  • バイオ医薬品賦形剤製造市場:企業規模別(2022年・2035年)
  • バイオ医薬品賦形剤製造市場:経営規模別(2022年・2035年)
  • バイオ医薬品賦形剤製造市場:地域別(2022年・2035年)
    • 北米のバイオ医薬品賦形剤製造市場(2022年~2035年)
    • 欧州のバイオ医薬品賦形剤製造市場(2022年~2035年)
    • アジア太平洋のバイオ医薬品賦形剤製造市場(2022年~2035年)
    • ラテンアメリカのバイオ医薬品賦形剤製造市場(2022年~2035年)
    • 中東・北アフリカのバイオ医薬品賦形剤製造市場(2022年~2035年)
    • その他の地域のバイオ医薬品賦形剤製造市場(2022年~2035年)

第11章 結論

第12章 経営陣の考察

  • 章の概要
  • DFE Pharma

第13章 付録1:データの表

第14章 付録2:企業と組織のリスト

目次
Product Code: HCR 1562

Biopharmaceutical Excipient Overview

The Biopharmaceutical Excipient Manufacturing Market size is forecast to reach USD 5,888.0 Million by 2035, after growing at a CAGR of 4.9% during 2023-2035. The major driving forces of this market are increasing incidences of chronic diseases owing to sedentary lifestyles; substantial investments by pharmaceutical companies in the development of medicines; and the implementation of new techniques such as nanotechnology. For instance, according to the World Health Organization, by around 2050, chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory illnesses will account for 86% of the 90 million deaths each year: a staggering 90% increase in absolute numbers, since 2019. However, the major challenges currently faced by the biopharmaceutical industry are the side effects of drugs; and developing environmental-friendly manufacturing processes.

Report Coverage

The report "Biopharmaceutical Excipient Manufacturing Market- Forecast (2023-2035)", by IndustryARC, covers an in-depth analysis of the following segments of the Biopharmaceutical Excipient Manufacturing market.

Distribution by Type of Excipient based on Chemical Composition: Carbohydrates, Polyols, Polymers, Proteins / amino acids, Salts, Lipids, Others,

Distribution by Type of Excipient based on Function: Surfactants, Stabilizers, Tonicity modifiers, Bulking agents, Buffering agents, Solubility enhancers, Drug delivery system, Chelators, Antimicrobials, Antioxidants, and Others;

Distribution by Type of Excipient based on Chemical Structure: Organic, Inorganic;

Distribution by Scale of Operation: Preclinical, Clinical, Commercial;

Distribution by Type of Biologic: Vaccines, Proteins / peptides, Cell therapies, Antibodies, Blood products;

Distribution by Company Size: Small, Mid-sized, Large, Very Large;

By Geography: North America, Europe, Asia-Pacific, Latin America, MENA, Rest of the World.

Key Takeaways

  • Europe is the world's largest market for biopharmaceutical excipients, with a leading market share of 33% in 2022. The European biopharmaceutical Excipients market is projected to grow with a CAGR of 4.1% from 2023 to 2035 with a market size of $1.03 billion in 2022 and $1.76 billion in 2035 owing to significant industrial growth in the region.
  • Pharmaceutical companies are slightly optimistic about economic conditions in North America and the Asia-Pacific due to positive momentum in the US, firm domestic demand, and strong government expenditure in India. Asia-Pacific is projected to grow with the fastest CAGR of 6.4% with a market size of $0.75 billion in 2022 and $1.71 billion in 2035.
  • Based on functions, Antimicrobials held the major market share of 24% in 2022. Excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling the pH and tonicity of the APIs. Additionally, biopharmaceutical excipients act as bulking agents, antioxidants, or preservatives.

Distribution by Type of Excipient based on Chemical Composition - Segment Analysis

Proteins/Amino Acids dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. This is due to rising consumer spending capacity and greater individual awareness of preventative care and healthy lifestyles. They are used in health supplements to relieve muscle soreness and fatigue, as well as to minimize the risk of cardiovascular disease. Because of the popularity of veganism and vegetarianism, there is a growing demand for plant-based protein sources. Because plant-based proteins usually lack one or more key amino acids, amino acid supplements are used to ensure that people on plant-based diets get enough nutrients. They are also found in nutritional supplements, which are growing more popular as individuals strive to improve their health and well-being. Amino acid supplements are marketed for their possible benefits in terms of muscle building, athletic performance, and overall health.

Distribution by Type of Excipient based on Function - Segment Analysis

Antimicrobials dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The antimicrobials industry is expected to increase quickly in recent years. The shift in growth trajectory is mostly due to firms resuming production after the COVID-19 epidemic, when demand increased considerably. With the exponential spread of coronavirus, the global antimicrobials market is predicted to grow significantly. Furthermore, the growing frequency of numerous bacterial infections would need the introduction of antimicrobials into the market. Antimicrobials are one of the most powerful types of chemotherapy and have been used to protect humans from infectious diseases. Antimicrobial agents destroy or delay microorganisms. Microorganisms include bacteria, viruses, protozoans, and fungi such as mold and mildew.

Distribution by Type of Excipient based on Chemical Structure - Segment Analysis

Organic dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. Growing pharmaceutical drug demand is predicted to drive the organic biopharmaceutical excipients market forward. Pharmaceutical drugs are chemical substances or compounds that are used to prevent, diagnose, treat, or relieve various diseases, medical conditions, or symptoms in humans. The increased need for pharmaceutical medications has increased the demand for organic pharmaceutical excipients, which provide acceptable and compatible constituents for organic drug formulations and aid in the physiological absorption of the drug. According to the European Federation of Pharmaceutical Industries and Associations, a Europe-based pharmaceutical industry association, global pharmaceuticals production increased by 4.6 percent in June 2022, from €286,697 million ($308,881 million) in 2020 to €300,000 ($323,214) in 2021.

Distribution by Scale of Operation - Segment Analysis

Clinical dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The biopharmaceutical excipient market in clinical operation is driven by the increasing demand for biopharmaceutical drugs, especially in the treatment of chronic diseases such as cancer, diabetes, and autoimmune disorders. Biopharmaceutical drugs have unique formulation requirements, and excipients play a crucial role in meeting these requirements. The U.S. Food and Drug Administration (FDA) approved BASF Solutions' Soluplus® branded excipient in 2022 as part of its initiative to assess the acceptance and security of excipients for use in clinical trials without regard to a particular New Drug Application. Excipients, or inactive substances, like the trademarked Soluplus® excipient, are essential for facilitating the drug development process for active pharmaceutical compounds that are poorly soluble. In addition, the continuous advancements in biotechnology and drug delivery technologies have led to the development of novel excipients that can enhance the drug's bioavailability, stability, and therapeutic efficacy. This drives the demand for innovative excipients in clinical operations.

Distribution by Type of Biologic - Segment Analysis

Vaccines dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The biopharmaceutical excipient market in vaccines is driven by the increasing demand for vaccines for preventive healthcare and disease control. In the creation of novel medications, biopharmaceuticals, and vaccinations to combat the coronavirus and other illnesses, excipients are essential. According to Excipient World, in 2020, a U.S.-based biotechnology firm has introduced Remdesivir an antiviral drug which emphasizes the crucial excipient that purified water had in the COVID-19 vaccine's development. With a population of over 330 million, the United States alone requires the production of at least 660 million doses of the COVID-19 vaccine. Millions of gallons of pharmaceutical-grade water are currently produced every day, most of which is used directly for vaccine development and testing. The rise in the production of vaccines is anticipated to drive the market growth.

Distribution by Company Size - Segment Analysis

Large dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. When it comes to large company size, several factors play a role in the biopharmaceutical excipient market. Large pharmaceutical companies typically have a greater demand for excipients due to their extensive drug portfolios and production scale. Mid-sized companies in biopharmaceutical excipient manufacturers include Kerry Group, Avantor, Lubrizol Corp, BASF, Roquette Freres, FMC Corp, Croda International, Ashland Global Holdings, and ABITEC. These companies often engage in extensive research and development activities, leading to the formulation of various biopharmaceutical drugs that require different excipients.

Geography - Segment Analysis

Europe Biopharmaceutical Excipient Manufacturing Market generated a revenue of $1.03 Million in 2022 and is projected to reach a revenue of $1.76 Million by 2035 growing at a CAGR of 4.1% during 2023-2035. By promoting the best use of excipients in medications, the International Pharmaceutical Excipients Council (IPEC) Europe produces standards to improve patient safety. Since 1992, IPEC Europe has brought together manufacturers, distributors, and users of pharmaceutical excipients. Because of rising healthcare costs and an aging population, Europe's pharmaceutical industry is booming. This rise fuels the demand for pharmaceutical excipients, which are used to create new medications and improve current ones. Excipients in biopharmaceuticals play an important role in increasing medication stability, solubility, and bioavailability. Drug formulation processes and excipient functions are constantly improving, which drives market expansion. In recent years, the discovery of biological medications has resulted in significant changes in the pharmaceutical industry environment. Large corporations have shifted their focus away from small molecule medications and toward the discovery and production of complex biological chemicals produced by a range of species.

Drivers - Biopharmaceutical Excipient Manufacturing Market

The growing emphasis of pharmaceutical companies on the generic market

Key market participants are concentrating on the development and commercialization of innovative biopharmaceutical excipients. DFE Pharma, for example, released a new excipient product line called 'BioHale' in April 2021 to address global supply difficulties for biopharmaceutical businesses. Furthermore, as demand for biopharmaceutical excipients grows, manufacturing facilities are expanding geographically. For example, in May 2022, DFE Pharma launched a new facility in India to provide pharmaceutical players with fast-track formulation services, including excipients, to obtain the proper formulations.

Multifunctional excipients are becoming more popular

Industry acceptance of multi-functional biopharmaceutical excipients is also driving market expansion. They are efficient and effective in improving the biopharmaceutical manufacturing process. Better product quality, increased production, and lower operational costs are all associated benefits. The success of COVID-19 vaccines is mostly dependent on their effectiveness, which has been improved by the use of efficient drug delivery systems; this provides enormously lucrative potential for market entities. Multifunctional excipients such as Ludiflash, F-MELT, and Avicel CE-15 have been created specifically for ODT formulations. They are custom-made to provide binding during compression (to produce a hard tablet at a low compression pressure) and quick disintegration when exposed to a medium. They are handled in such a way that they disintegrate with a creamier mouthfeel, boosting the formulation's overall palatability. In some situations (such as Ludiflash, which contains around 90% mannitol), the excipient itself gives a sweet taste to the product, reducing the need for sweetener in the formulation.

Challenges - Biopharmaceutical Excipient Manufacturing Market

Manufacturing complexity

Some biopharmaceutical excipients, such as lipids, have sophisticated and capital-intensive manufacturing procedures. As a result, demand for pharmaceutical excipients for biologics has increased significantly. However, the accompanying manufacturing procedures for some biopharmaceutical excipients, such as lipids, are highly sophisticated, capital-intensive, and fraught with several problems. Excipient variability, excipient concentrations, capital-intensive manufacturing procedures, multiple difficulties, viscosity, analytical characterisation, and isotonic formulations can all contribute to the complexity of biopharmaceutical excipient manufacturing.

Regulatory approval

Because innovative excipients do not have a separate approval process, they can only be approved for a specific function in a medication dosage formulation. Pharmaceutical excipient manufacturing standards face many challenges: There is no special approval mechanism in place for novel excipients, Excipients do not have regulatory status in the United States, Excipients used in pharmaceutical preparations are not subject to any strict criteria.

Market Landscape

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the Biopharmaceutical Excipient Manufacturing market. In 2021, the Biopharmaceutical Excipient Manufacturing Market share has been consolidated by the top ten players accounting for 38.3% of the share. Major players in the Biopharmaceutical Excipient Manufacturing Market are Dupont, Evonik, BASF, FMC Crop., Ashland. Merck, Cargill, and others.

Developments:

On 2nd June 2023, Evonik introduced cutting-edge peptides for biopharmaceutical applications. Evonik cQrex® KC is a peptide that improves cell culture media performance and is utilized in the production of biological medicines. The biopharmaceutical industry's media formulators and cell culture process developers may now optimize cystine supply and boost cell culture productivity thanks to this novel peptide. The newest product in Evonik's arsenal of cQrex® cell culture chemicals, cQrex® KC, is intended to boost productivity and efficiency in cell culture procedures that generate viral vectors, cell treatments, vaccines, and monoclonal antibodies.

On 1st September 2022, the science and technology company Merck introduced Sodium Chloride Granulated EMPROVE EXPERT Ph Eur, BP, ChP, JP, USP, a multi-compendial excipient with broad applications in both pharma and biopharma. This expands the company's granulated product line.

On April 21, 2021, DFE Pharma, a German-based provider of biopharmaceutical excipient solutions, announced the launch of BioHale, a new product line designed to help biopharmaceutical firms with their global supply issues. The new line will supply manufacturers and drug developers with high-quality excipient technology and services to promote therapeutic formulation, as well as market purity and low endotoxin excipients for use in the formulation.

Table of Contents

1.PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Biopharmaceutical Excipients
  • 3.3. Properties of Ideal Excipients
  • 3.4. Classification of Biopharmaceutical Excipients
    • 3.4.1. Classification based on Route of Administration
    • 3.4.2. Classification of Excipients based on Structure
    • 3.4.3. Classification of Excipients based on Function
    • 3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms
  • 3.5. Applications of Biopharmaceutical Excipients
  • 3.6. Regulatory Scenario
  • 3.7. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
    • 4.2.5. Analysis by Type of Excipient based on Chemical Composition
  • Carbohydrates
  • Polyols
  • Polymers
  • Proteins / amino acids
  • Salts
  • Lipids
  • Others
    • 4.2.6. Analysis by Type of Excipient based on Function
  • Surfactants
  • Stabilizers
  • Tonicity modifiers
  • Bulking agents
  • Buffering agents
  • Solubility enhancers
  • Drug delivery system
  • Chelators
  • Antimicrobials
  • Antioxidants
  • Others
    • 4.2.7. Analysis by Type of Excipient based on Chemical Structure
  • Organic
  • Inorganic
    • 4.2.8. Analysis by Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
    • 4.2.9. Analysis by Type of Formulation
  • Liquid or parenteral
  • Solid
    • 4.2.10. Analysis by Type of Biologic
  • Vaccines
  • Proteins / peptides
  • Cell therapies
  • Antibodies
  • Blood products
    • 4.2.11. Analysis by Global Regulatory Compliance
  • United States Pharmacopoeia / United States Pharmacopoeia-National Formulary
  • European Pharmacopoeia
  • Japanese Pharmacopoeia
  • British Pharmacopoeia
  • China Pharmacopoeia
  • American Chemical Society grade
  • Indian Pharmacopoeia
  • Food Chemical Codex
  • Taiwan FDA

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
    • 5.4.1. Company Competitiveness Analysis: Small Companies
    • 5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
    • 5.4.3. Company Competitiveness Analysis: Large Companies
    • 5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS

  • 6.1. Chapter Overview
  • 6.2. ABITEC
    • 6.2.1. Company Overview
    • 6.2.2. Biopharmaceutical Excipient Offerings
    • 6.2.3. Manufacturing Facilities
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Avantor
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Biopharmaceutical Excipient Offerings
    • 6.3.4. Manufacturing Facilities
    • 6.3.5. Recent Developments and Future Outlook
  • 6.4. BASF Pharma
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Biopharmaceutical Excipient Offerings
    • 6.4.4. Manufacturing Facilities
    • 6.4.5. Recent Developments and Future Outlook
  • 6.5. Corden Pharma
    • 6.5.1. Company Overview
    • 6.5.2. Biopharmaceutical Excipient Service Offerings
    • 6.5.3. Manufacturing Facilities
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. DFE Pharma
    • 6.6.1. Company Overview
    • 6.6.2. Biopharmaceutical Excipient Offerings
    • 6.6.3. Manufacturing Facilities
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Evonik
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Biopharmaceutical Excipient Offerings
    • 6.7.4. Manufacturing Facilities
    • 6.7.5. Recent Developments and Future Outlook
  • 6.8. Kirsch Pharma
    • 6.8.1. Company Overview
    • 6.8.2. Biopharmaceutical Excipient Offerings
    • 6.8.3. Manufacturing Facilities
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. Merck KGaA
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Biopharmaceutical Excipient Offerings
    • 6.9.4. Manufacturing Facilities
    • 6.9.5. Recent Developments and Future Outlook
  • 6.10. Pfanstiehl
    • 6.10.1. Company Overview
    • 6.10.2. Biopharmaceutical Excipient Offerings
    • 6.10.3. Manufacturing Facilities
    • 6.10.4. Recent Developments and Future Outlook
  • 6.11. Roquette
    • 6.11.1. Company Overview
    • 6.11.2. Biopharmaceutical Excipient Offerings
    • 6.11.3. Manufacturing Facilities
    • 6.11.4. Recent Developments and Future Outlook
  • 6.12. Spectrum Chemical Manufacturing
    • 6.12.1. Company Overview
    • 6.12.2. Biopharmaceutical Excipient Offerings
    • 6.12.3. Manufacturing Facilities
    • 6.12.4. Recent Developments and Future Outlook
  • 6.13. SPI Pharma
    • 6.13.1. Company Overview
    • 6.13.2. Biopharmaceutical Excipient Offerings
    • 6.13.3. Manufacturing Facilities
    • 6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Chapter Overview
  • 7.2. Partnership Models
  • 7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
    • 7.3.1. Analysis by Year of Partnership
    • 7.3.2. Analysis by Type of Partnership
    • 7.3.3. Analysis by Year and Type of Partnership
    • 7.3.4. Analysis by Type of Excipient
    • 7.3.5. Analysis by Type of Drug Molecule
    • 7.3.5. Most Active Players: Analysis by Number of Partnerships
    • 7.3.6. Analysis by Geography
      • 7.3.6.1. Intercontinental and Intracontinental Deals
      • 7.3.6.2. International and Local Deals

8. RECENT EXPANSIONS

  • 8.1. Chapter Overview
  • 8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
    • 8.2.1. Analysis by Year of Expansion
    • 8.2.2. Analysis by Type of Expansion
    • 8.2.3. Analysis by Company Size and Location of Headquarters
    • 8.2.4. Analysis by Location of Expanded Facility
    • 8.2.5. Analysis by Type of Excipient
    • 8.2.6. Analysis by Type of Drug Molecule
    • 8.2.7. Most Active Players: Analysis by Number of Recent Expansions
    • 8.2.8. Geographical Analysis
      • 8.2.8.1. Region-wise Distribution
      • 8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
    • 9.3.1. Analysis by Company Size
    • 9.3.2. Analysis by Scale of Operation
    • 9.3.3. Analysis by Location of Manufacturing Facility
  • 9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
  • 10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
  • 10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
  • 10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
  • 10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
  • 10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
    • 10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
    • 10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
    • 10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
    • 10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
    • 10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
    • 10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. DFE Pharma
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS